Under the supervision of established investigator Dr. Marilyne Labrie, this project aims to study how oncolytic viruses change the immune microenvironment of ovarian cancer. Studies will be performed using mouse ovarian cancer cell lines that have been genetically modified to reproduce the alterations frequently observed in human patients. These research models will enable the team to characterize the efficacy of virotherapies based on the molecular profile of tumour cells, representing a first step toward personalized treatment with oncolytic viruses for women with ovarian cancer.